Treatment outcomes following continuous miglustat therapy in
Por um escritor misterioso
Last updated 29 março 2025

Background Niemann-Pick disease Type C (NP-C) is a rare, progressive neurodegenerative disorder characterized by progressive neurodegeneration and premature death. We report data at closure of the NPC Registry that describes the natural history, disease course and treatment experience of NP-C patients in a real-world setting. Methods The NPC Registry was a prospective observational cohort study that ran between September 2009 and October 2017. Patients with a confirmed diagnosis of NP-C were enrolled regardless of treatment status. All patients underwent clinical assessments and medical care as determined by their physicians; data were collected through a secure internet-based portal. Results At closure on October 19, 2017, 472 patients from 22 countries were enrolled in the NPC Registry. Mean (standard deviation) age at enrollment was 21.2 (15.0) years, and 51.9% of patients were male. First neurological symptom onset occurred during the early-infantile (< 2 years), late-infantile (2 to < 6 years), juvenile (6 to < 15 years), or adolescent/adult (≥ 15 years) periods in 13.5, 25.6, 31.8, and 29.1% of cases, respectively. The most frequent neurological manifestations prior to enrollment included ataxia (67.9%), vertical supranuclear gaze palsy (67.4%), dysarthria (64.7%), cognitive impairment (62.7%), dysphagia (49.1%), and dystonia (40.2%). During infancy, splenomegaly and hepatomegaly were frequent (n = 199/398 [50%] and n = 147/397 [37.0%], respectively) and persisted in most affected patients. Of the 472 enrolled patients, 241 were continuously treated with miglustat during the NPC Registry observation period, of whom 172 of these 241 patients were treated continuously for ≥12 months. A composite disability score that assesses impairment of ambulation, manipulation, language, and swallowing was highest in the early-infantile population and lowest in the adolescent/adult population. Among the continuous miglustat therapy population, 70.5% of patients had improved or had stable disease (at least 3 of the 4 domains having a decreased or unchanged score between enrollment and last follow-up). The NPC Registry did not identify any new safety signals associated with miglustat therapy. Conclusions The profiles of clinical manifestations in the final NPC Registry dataset agreed with previous clinical descriptions. Miglustat therapy was associated with a stabilization of neurological manifestations in most patients. The safety and tolerability of miglustat therapy was consistent with previous reports.

Frontiers Therapeutic Strategies For Tay-Sachs Disease

EP2796457A1 - Genz 112638 for treating Gaucher or Fabry disease in

Therapeutic advantages of combined gene/cell therapy strategies in

Long term follow-up to evaluate the efficacy of miglustat

Opfolda: Package Insert

Randomized, controlled trial of miglustat in Gaucher's disease

Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized

Recommendations for oral treatment for adult patients with type 1

PDF] Miglustat for treatment of Niemann-Pick C disease: a

Full article: New therapies in the management of Niemann-Pick type

Treatment outcomes following continuous miglustat therapy in

CNS-accessible Inhibitor of Glucosylceramide Synthase for
Recomendado para você
-
Niemann-Pick Type C « Niemann-Pick Children's Fund, Inc29 março 2025
-
A new regulatory mechanism of STARD1 in Niemann-Pick disease type C (NPC), discovered29 março 2025
-
NNPDF on X: October is Global Niemann-Pick Disease Awareness Month! For more information on Niemann-Pick Disease or to make a donation to NNPDF go to #niemannpick #ASMD #NPC #raredisease #NNPDF #NiemannPickC29 março 2025
-
Anesthetic consideration of Niemann-Pick Disease type C29 março 2025
-
Niemann-Pick disease - Breda Genetics srl Breda Genetics srl29 março 2025
-
Niemann-Pick Disease, Types A and B29 março 2025
-
Fig 2. Subcortical Volumetric Reductions in Adult Niemann-Pick29 março 2025
-
Miglustat for treatment of Niemann-Pick C disease: a randomised29 março 2025
-
Niemann-Pick Diseases - The Medical Biochemistry Page29 março 2025
-
Gene therapy shows promise for treating Niemann-Pick disease type29 março 2025
você pode gostar
-
Greatest achievement in gaming: Flappy Bird - Fextralife29 março 2025
-
From the Minds Behind the Danganronpa Series, Master Detective Archives: RAIN CODE - DLC 3 for Nintendo Switch™ Featuring Protagonist Halara Nightmare is Available Now - Spike Chunsoft29 março 2025
-
The Weather and Temperature in Tokyo by Month29 março 2025
-
Free Printable Bridal Shower Word Mining Game29 março 2025
-
Meloetta (85/162) [XY: BREAKthrough]29 março 2025
-
One-Hit Wonder29 março 2025
-
Gochuumon wa Usagi Desu ka? Character Song 1 - Cocoa & Chino29 março 2025
-
Resident Evil: The Final Chapter Begins Production, Full Cast and Plot Synopsis Revealed29 março 2025
-
TNT Estampado para Festa Junina - Grupo Cad's29 março 2025
-
How to play online with yuzu emulator !!! (2022)29 março 2025